ClinicalTrials.Veeva

Menu

Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study

G

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Status

Unknown

Conditions

Overactive Bladder

Treatments

Drug: Solifenacin Succinate
Device: Electroacupuncture
Device: Sham Electroacupuncture

Study type

Interventional

Funder types

Other

Identifiers

NCT02452879
Z121107001012148

Details and patient eligibility

About

The purpose of this study is to determine whether electroacupuncture is effective in the treatment of overactive bladder.

Full description

Patient registry: Participants experiencing overactive bladder will be recruited from hospital outpatients and clinic-community. the diagnosis was made by the urologists. the random number table was generated by the Computer.

Sample size: According to the preliminary experiment combined the literature. Sample size is based on the primary outcome. The first step: one-tailed test: the electroacupuncture group vs Solifenacin group is 79.5% VS 54.8%( α=0.05, β=0.20, n=51). The second step: two-tailed test :the electroacupuncture group vs Placebo group is 54.5% VS 20.9%,(α=0.05, β=0.20, n=37). To combine the first and second step, 51 cases in each group are needed. Allowing for a 10% dropout, 57 cases in each group are needed. So we set the sample size is 60.

Quality control

  1. Strict training on staff participating in the trial.
  2. Rigorous control of the process of randomization.
  3. Specific inclusion and exclusion criteria.
  4. Strict outcome assessors and statisticians.
  5. The standard of the drugs, acupuncture apparatus, inspection equipment are consistant.
  6. Outcome assessment, completion of case report forms and data management will be under strict supervision.

Enrollment

180 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Clinical diagnosis of overactive bladder.
  2. Frequent micturition.(average urinary frequency of ≥8 voids per day)
  3. No relevant drug use within 2 weeks and no acupuncture treatment within 1 month before the study; not in other clinical trials.
  4. Self-reported bladder symptoms ≥3 months
  5. Capable of giving informed consent .
  6. Capable and willing to follow all study-related procedures

Exclusion criteria

  • Frequent micturition and urinary urgency are secondary to other diseases.
  • Clinical diagnosis of simple stress urinary incontinence.
  • Patients with urinary track infection and vagenal infection.
  • Patients with implantable pelvic stimulator.
  • Current use of electric therapy on pelvic area/back/legs.
  • Current use of clostridium botulinum therapy on vesical or pelvic muscles.
  • participation in any clinical inverstigation involving or impacting gynecological/urinary/renal function.
  • Suffering from severe cardiac/hepatic/renal injury or cognitive disorder/aphasia/ dysphrenia/malnutrition, or in poor perform status and unable to cooperate.
  • Patients in gestation and in lactation period.
  • Patients in coagulation disorders or taking anticoagulation drugs.
  • People with cardiac pacemaker or metal allergy.
  • Patients having got eletroacupunture therapy or solifenacin in 4 weeks before the study.
  • Patients are afraid of needles.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

180 participants in 3 patient groups, including a placebo group

Electroacupuncture group
Experimental group
Description:
Needle on bilateral BL33 acupoint 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day. The treatment period lasts eight weeks. totally 24 times.30min/time.
Treatment:
Device: Electroacupuncture
Placebo group
Placebo Comparator group
Description:
with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
Treatment:
Device: Sham Electroacupuncture
Solifenacin Succinate group
Active Comparator group
Description:
Solifenacin Succinate Tablets (made by the Anse Tailai Pharmaceutical (China) R \& D limited company) 5mg, 1 tablets each time, 1 times / day, oral administration of 30min before meal, even for 8 weeks.
Treatment:
Drug: Solifenacin Succinate

Trial contacts and locations

1

Loading...

Central trial contact

Jia Baohui, Master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems